Objective: To assess the frequency of risk factors for rhabdomyolysis with simvastatin and
atorvastatin in cases reported to the Australian Adverse Drug Reactions Advisory Committee …

Rhabdomyolysis is a serious adverse drug reaction of statins. There are few studies
comparing the risk of rhabdomyolysis between the different statins. Using the WHO …

Purpose To identify and characterize risk factors for rhabdomyolysis in patients prescribed
statin monotherapy or statin plus fibrate therapy. Methods A nested case‐control study was …

Purpose To assess spontaneous reports of rhabdomyolysis associated with simvastatin (SV)
and pravastatin (PV) for evidence of CYP3A4 interaction. Clinical trial results advocate …

Background Two randomised controlled trials have found a higher risk of rhabdomyolysis in
users of 80 mg versus 20 mg simvastatin, but there is very limited information about the risk …

OBJECTIVE: To determine the number of cases of statin-associated rhabdomyolysis
reported to the Food and Drug Administration for 6 statins and to profile the cases …

Context Elevated total cholesterol (total‐C) and low‐density lipoprotein cholesterol (LDL‐C)
levels are established risk factors for cardiovascular disease (CVD). HMG‐CoA reductase …

Background Statins have a well-established role in prevention of vascular events but are
associated with muscle-related adverse events. The dose relationship with these adverse …

Background: Simvastatin, a 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitor, is
indicated for the treatment of hypercholesterolemia and plays an important role in both the …

BACKGROUND: The occurrence of low rates of rhabdomyolysis among patients receiving
lipid-lowering drugs (LLDs) in randomized clinical trials may be elucidated with population …